I'm not sure what, if anything, is new (to us) in this SGEN press release, which was just issued. Here's the first part, followed by a link to the rest:
Seattle Genetics Announces ADCETRIS® Clinical Data to be Reported in Multiple Presentations at ASCO Annual Meeting -70 percent objective response rate in retreatment trial-
-Multiple objective responses observed in CD30-positive non-Hodgkin lymphoma patients, including four of seven patients with diffuse large B-cell lymphoma-
-First report of CD30 expression from comprehensive screening in broad range of non-lymphoma malignancies-
CHICAGO--(BUSINESS WIRE)--Jun. 2, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL. Data demonstrate the activity and tolerability when patients are retreated with ADCETRIS, the activity and tolerability of ADCETRIS in CD30-positive non-Hodgkin lymphomas and CD30 expression from a screening protocol in non-lymphoma malignancies. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30.
“Our goal is for ADCETRIS to become the foundation of therapy for CD30-positive malignancies and, to that end, we are aggressively investing in its clinical development and broadly exploring CD30 expression across numerous cancer types,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “Our data presentations at ASCO highlight the potential for ADCETRIS and reinforce our development strategy to generate data that will support stepwise growth of ADCETRIS for patients with CD30-expressing malignancies.”
Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: a phase II study (Abstract #8027)
In a phase II trial, patients who previously responded to treatment with ADCETRIS, then discontinued treatment and subsequently had disease progression or relapse were eligible for retreatment. Data were reported from 24 patients treated to date on the study, including 16 with Hodgkin lymphoma (HL) and eight with systemic anaplastic large cell lymphoma (sALCL). Patients had received a median of four prior systemic therapies, including ADCETRIS. Key findings include:...
I found the sidestepping analogy to increasing the use of Adcetris to be a continuance of a growth strategy that I continue to support.
However, I found that the CD-30 Expression cases in non lymphomic cancers were 2% of the tested population. This does not appear to be a substantial number of cases and if correct on a full 3,000 patient sampling there will only be 60 cases then are the costs of these trials worth the benefits? or is the added users continue to validate any CD-30 expression cancer should utilize Adcetris and continue a growth pattern for its use? I guess I am shocked at the low percentage of CD-30 expression in the non lymphoma patients.
The response rates are impressive and was wondering whether there is thought of Adcetris as a type of vaccine usage that would substantially reduce recurrence with reduced dosage so that there is less adverse effects? Not sure that dosage reduction aligns with linear reduction in AEs.
Jack, these are the numbers that are important for non-lymphoid cancers:
The most common malignancies with CD30 expression were mesothelioma (5 of 18 patients; 28 percent), melanoma (6 of 64 patients; 9 percent), triple negative breast cancer (4 of 71 patients; 6 percent) and ovarian carcinoma (9 of 173 patients; 5 percent).
For subsequent trials, SGEN will focus on screening and treating those subset of cancer patients that show high % of CD30 expressors.
"Melanoma, the most serious type of skin cancer, will account for more than 75,000 cases of skin cancer in 2012. It accounts for almost 9,000 of the nearly 12,000 skin cancer deaths each year."
Mesothelioma is also rare. However, if CD30 occurs at a high rate in these cancer patients, and Adcetris has less AEs than current SOC, then that adds to market size.